Latest Stock Market News

On the derivative front, the strike of 19,300 saw the highest addition of put open interest (OI). In contrast, the strike of 19,500 continued to possess the highest call OI, indicating immediate support and resistance.

Net commission for the quarter stood at Rs 6,077 crore, compared with Rs 5,808 crore a year ago. The solvency ratio as of September-end stood at 1.90 times, compared with 1.88 times a year ago. The gross non-performing assets ratio as of September 30 was 2.43%, compared with 5.60% a year ago, and 2.48% a quarter ago.

“The next one year may not be very exciting for value investors because all of us know it is very rich valuations in general, so we have to go bottom-up stock pickers or business pickers, very selective, looking at the future of these companies and the verticals they are operating in and that way it is exciting. But in general, hurrying to pick stocks at these valuations, is not going to work.”

EBITDA for the quarter increased by 68% YoY to Rs 900 crore, representing an EBITDA margin of 25% versus 22% in the same period last year. The gross R&D spends grew 10% YoY to Rs 278 crore in Q2FY24.

The downfall in the markets saw benchmark indices hit their 52-week lows on March 20, 2023. From its December highs, the index had corrected about 11%

The Mudrex Muhurat Investing event is all about making the investment journey smoother, more rewarding, and auspicious. The platform invites investors to join them on November 12th, where they can seize the moment and make the most of this special occasion.

Several large and midcap stocks exhibited notable strength, surpassing their 100-day Simple Moving Average (SMA) on November 9.

On November 10, Friday, Trendlyne reported a golden opportunity in the stock market with over 40 Nifty stocks showcasing the Golden Crossover. This article explores the concept of the Golden Crossover and spotlights 5 stocks handpicked by ETMarkets, shedding light on the importance of this pattern in shaping investment decisions.

“This year, there is no need for immediate cash infusion in Apollo HealthCo. It is being supported by Rs 130 crore of EBITDA coming from the backend pharmacy. So, there is cash for growth existing within the company and at the right valuation, we will look at a 10% dilution.”